Traws Pharma Announces Antiviral Program Targeting Ongoing Hantavirus and Ebola Virus Disease Outbreaks
Traws Pharma, a clinical-stage biopharmaceutical company, announced the advancement of a novel proprietary broad-spectrum antiviral combination designed to combat Hantavirus, Ebola, and Lassa viruses using a unique dual-strike mechanism. The therapy leverages host nucleotide depletion and forced lethal incorporation to halt viral replication effect…